AR055113A1 - Piperazinas acetilenicas como antagonistas de receptores de glutamato metabotropicos - Google Patents
Piperazinas acetilenicas como antagonistas de receptores de glutamato metabotropicosInfo
- Publication number
- AR055113A1 AR055113A1 ARP060103440A ARP060103440A AR055113A1 AR 055113 A1 AR055113 A1 AR 055113A1 AR P060103440 A ARP060103440 A AR P060103440A AR P060103440 A ARP060103440 A AR P060103440A AR 055113 A1 AR055113 A1 AR 055113A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- alkylhalo
- co2r2
- so2r2
- Prior art date
Links
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 title abstract 2
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 3
- -1 OC1-6 alkylhalo Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 abstract 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229920002554 vinyl polymer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
También se incluyen composiciones farmacéuticas y usos y procesos para elaborar compuestos, así como métodos para el tratamiento médico de trastornos mediados por mGluR 5. Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1) en donde: Ar1 es un grupo arilo o heteroarilo opcionalmente sustituido, en donde los sustituyentes se seleccionan del grupo formado por F, Cl, Br, I, OH, nitro, C1-6 alquilo, C1-6 alquilhalo, OC1-6 alquilo, OC1-6 alquilhalo, C2-6 alquenilo, C2-6 alquinilo, -CN, CO2R2, SR2, S(O)R2, SO2R2, arilo, heteroarilo, cicloalquilo y heterocicloalquilo, en donde cualquier grupo cíclico puede ser adicionalmente sustituido con al menos un sustituyente seleccionado del grupo formado por F, Cl, Br, I, OH, nitro, C1-6 alquilo, C1-6 alquilhalo, OC1-6 alquilo, OC1-6 alquilhalo, C2-6 alquenilo, C2-6 alquinilo, -CN, CO2R2, SR2, S(O)R2 y SO2R2; A se selecciona del grupo formado por Ar1, CO2R2, CONR2R3, S(O)R2 y SO2R2; B se selecciona del grupo formado por vinileno y etinileno, en donde el grupo vinileno está opcionalmente sustituido con hasta 2 grupos C1-6 alquilo seleccionados en forma independiente; R1, en cada caso, se selecciona en forma independiente del grupo formado por F, Cl, Br, I, OH, CN, nitro, C1-6 alquilo, C1-6, OC1-6 alquilo, C1-6 alquilhalo, OC1-6 alquilhalo, (CO)R2, O(CO)R2, O(CO)OR2, CO2R2, -CONR2R3, C1-6 alquilenoOR2, OC2-6 alquilenoOR2 y C1-6 alquilenociano; R2 y R3 se seleccionan en forma independiente del grupo formado por H, C1-6 alquilo, C1-6 alquilhalo, C2-6 alquenilo, C2-6 alquinilo y cicloalquilo; m es un entero seleccionado del grupo formado por 0, 1, 2, 3 y 4; y n es un entero seleccionado del grupo formado por 1, 2 y 3; o una sal aceptable para uso farmacéutico, hidrato, solvato, isoforma, tautomero, somero optico, o combinacion de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70794405P | 2005-08-15 | 2005-08-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR055113A1 true AR055113A1 (es) | 2007-08-08 |
Family
ID=37670907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060103440A AR055113A1 (es) | 2005-08-15 | 2006-08-08 | Piperazinas acetilenicas como antagonistas de receptores de glutamato metabotropicos |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20080194571A1 (es) |
| EP (1) | EP1919915A2 (es) |
| JP (1) | JP2009504736A (es) |
| KR (1) | KR20080050569A (es) |
| CN (1) | CN101248076A (es) |
| AR (1) | AR055113A1 (es) |
| AU (1) | AU2006280233A1 (es) |
| BR (1) | BRPI0614481A2 (es) |
| CA (1) | CA2616318A1 (es) |
| IL (1) | IL188807A0 (es) |
| MX (1) | MX2008001608A (es) |
| NO (1) | NO20080669L (es) |
| TW (1) | TW200801005A (es) |
| UY (1) | UY29733A1 (es) |
| WO (1) | WO2007021575A2 (es) |
| ZA (1) | ZA200801033B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090061041A (ko) | 2006-09-11 | 2009-06-15 | 노파르티스 아게 | 대사성 글루타메이트 수용체의 조절제로서의 니코틴산 유도체 |
| BRPI0818560A2 (pt) * | 2007-10-12 | 2019-09-24 | Novartis Ag | compostos orgânicos |
| WO2009047303A2 (en) * | 2007-10-12 | 2009-04-16 | Novartis Ag | Metabotropic glutamate receptor modulators for the treatment of pervasive developmental disorder |
| EP2826478A1 (en) | 2008-06-30 | 2015-01-21 | Novartis AG | Combinations comprising mglur modulators for the treatment of parkinson's disease |
| BR112012027816A2 (pt) | 2010-04-30 | 2017-08-08 | Novartis Ag | marcadores preditivos úteis no tratamento da síndrome do x frágil (fxs). |
| WO2013131981A1 (en) | 2012-03-08 | 2013-09-12 | Novartis Ag | Predictive markers useful in the diagnosis and treatment of fragile x syndrome (fxs) |
| CA3088288A1 (en) * | 2018-01-26 | 2019-08-01 | Recordati Industria Chimica E Farmaceutica S.P.A | Triazole, imidazole and pyrrole condensed piperazine derivatives and their use as modulators of mglu5 receptors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6231833B1 (en) * | 1999-08-05 | 2001-05-15 | Pfizer Inc | 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors |
| CZ192998A3 (cs) * | 1995-12-21 | 1999-05-12 | Pfizer Inc. | 2,7-Substituované oktahydropyrrolo[1,2-a]pyrazinové deriváty, meziprodukty pro jejich výrobu a farmaceutické prostředky na jejich bázi |
| EP0982030A3 (en) * | 1998-08-17 | 2000-05-10 | Pfizer Products Inc. | 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands |
| WO2001032660A1 (en) * | 1999-11-05 | 2001-05-10 | Nps Allelix Corp. | Compounds having 5-ht6 receptor antagonist activity |
| AU2003229535A1 (en) * | 2002-06-06 | 2003-12-22 | Novo Nordisk A/S | Substituted hexahydropyrrolo(1,2-a)pyrazines, octahydropyrido(1,2-a)pyrazines and decahydropyrazino(1,2-a)azepines |
-
2006
- 2006-08-03 TW TW095128477A patent/TW200801005A/zh unknown
- 2006-08-04 CN CNA2006800284539A patent/CN101248076A/zh active Pending
- 2006-08-04 EP EP06789373A patent/EP1919915A2/en not_active Withdrawn
- 2006-08-04 JP JP2008526975A patent/JP2009504736A/ja active Pending
- 2006-08-04 US US11/997,523 patent/US20080194571A1/en not_active Abandoned
- 2006-08-04 US US11/498,836 patent/US20070037817A1/en not_active Abandoned
- 2006-08-04 WO PCT/US2006/030394 patent/WO2007021575A2/en not_active Ceased
- 2006-08-04 MX MX2008001608A patent/MX2008001608A/es not_active Application Discontinuation
- 2006-08-04 KR KR1020087003196A patent/KR20080050569A/ko not_active Withdrawn
- 2006-08-04 BR BRPI0614481A patent/BRPI0614481A2/pt not_active IP Right Cessation
- 2006-08-04 AU AU2006280233A patent/AU2006280233A1/en not_active Abandoned
- 2006-08-04 CA CA002616318A patent/CA2616318A1/en not_active Abandoned
- 2006-08-08 AR ARP060103440A patent/AR055113A1/es unknown
- 2006-08-08 UY UY29733A patent/UY29733A1/es not_active Application Discontinuation
-
2008
- 2008-01-16 IL IL188807A patent/IL188807A0/en unknown
- 2008-01-31 ZA ZA200801033A patent/ZA200801033B/xx unknown
- 2008-02-05 NO NO20080669A patent/NO20080669L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20070037817A1 (en) | 2007-02-15 |
| UY29733A1 (es) | 2007-02-28 |
| US20080194571A1 (en) | 2008-08-14 |
| NO20080669L (no) | 2008-05-15 |
| BRPI0614481A2 (pt) | 2017-06-06 |
| CA2616318A1 (en) | 2007-02-22 |
| KR20080050569A (ko) | 2008-06-09 |
| EP1919915A2 (en) | 2008-05-14 |
| WO2007021575A3 (en) | 2007-04-05 |
| WO2007021575A2 (en) | 2007-02-22 |
| TW200801005A (en) | 2008-01-01 |
| ZA200801033B (en) | 2009-01-28 |
| MX2008001608A (es) | 2008-04-14 |
| JP2009504736A (ja) | 2009-02-05 |
| AU2006280233A1 (en) | 2007-02-22 |
| IL188807A0 (en) | 2008-08-07 |
| CN101248076A (zh) | 2008-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| MX2021013075A (es) | Oxisteroles y metodos de uso de los mismos. | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| PE20190395A1 (es) | Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos | |
| AR110139A1 (es) | COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| UY29058A1 (es) | Compuestos de isoindolona y su uso como potenciadores del receptor metabotropico de glutamato | |
| EA201890086A1 (ru) | 1,4-замещенные производные пиперидина | |
| UY28526A1 (es) | Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos | |
| BRPI0408068A (pt) | derivados de 5-feniltiazol e seus usos como inibidores de pi3 cinase | |
| AR085283A1 (es) | Antagonistas de hepcidina a base de sulfonaminoquinolina | |
| EA200501332A1 (ru) | Производные пиримидин-4-она и их применение в качестве модуляторов киназы p38 | |
| UY31524A1 (es) | Nuevos compuestos 010 | |
| EA201001682A1 (ru) | Производные фенил- и бензодиоксинилзамещенных индазолов | |
| CY1107301T1 (el) | Ιμιδαζο και θειαζολοπυριδινες ως αναστολεις κινασης jak3 | |
| CY1116885T1 (el) | Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου | |
| AR047966A1 (es) | Compuestos poliheterociclicos y su uso como antagonistas del receptor de glutamato metabotropico | |
| AR044614A1 (es) | Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4) | |
| SE0403171D0 (sv) | New compounds | |
| AR057728A1 (es) | Piperazinas sustituidas como antagonistas de receptores de glutamato metabotropicos. composiciones farmaceuticas. | |
| AR097894A1 (es) | Inhibidores terapéuticos de cdk8 o uso de los mismos | |
| EA201791671A1 (ru) | 4-замещенные соединения бензоксаборола и их применение | |
| MX2021012248A (es) | Polimorfos de voruciclib y metodos de elaboracion y uso de los mismos. | |
| AR061185A1 (es) | Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas. | |
| CO6150157A2 (es) | Derivados de 7-alquinil-1,8- naftiridonas su preparacion y su aplicacion en terapeutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |